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ABSTRACT 
Objectives: Serum adiponectin and leptin levels have been shown to be related to obesity, in-
sulin resistance and cardiovascular diseases (CVD). Opium addiction has a positive associa-
tion with endocrine system disorders. The relationship between adipokines and opium addic-
tion is unclear. In the present study, we aimed to determine serum adiponectin and leptin lev-
els in opium addicted subjects. 
Methods: 176 men, 88 opium addicts and 88 non- addicts were randomly selected from sub-
jects who participated in Kerman Coronary Artery Disease Risk factors Study (KERCADRS); 
a population-based study. Serum adiponectin and leptin levels were measured using ELISA 
and compared between two groups. We adjusted the effect of some confounding factors such 
as the patients’ demographic, clinical and medical history in multivariate analysis model. 
Results: The serum level of adiponectin in opium addicts was significantly lower than control 
group (6.5±3.6 vs. 9.8±8.1 µg/ml, P<0.001). There was no significant difference in serum lep-
tin level between two groups (11.8±10.3 ng/ml in control group vs. 11.5±10.8 ng/ml in opium 
addicts, p = 0.80). In the multivariate analysis, after adjusting for age, cigarette smoking, body 
mass index, type 2 diabetes, hypertension, cholesterol, triglyceride and high and low density 
lipoproteins, the negative association between opium addiction and decreased adiponectin 
level was still present (β = -0.144, P value = 0.005). 
Conclusions: The results showed that opium addiction reduces serum adiponectin level. Since 
adiponectin has been shown to have anti-diabetic and anti-atherogenic effects, its reduction 
may account for increase in the risk of metabolic disorders such as insulin resistance and 
CVD amongst opium addicted patients. 
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INTRODUCTION 
Opium addiction is one of the social and 
economic problems that many societies in 
the world are dealing with, especially coun-
tries in the Middle East (UNODC, 2010). 
The drug most abused in Western countries 
is heroine and most researchers have fo-
cused on the effect of heroine on body sys-
tems. In Iran, opium which contains many 
alkaloids along with morphine is the most 
common drug abused (UNODC, 2010). 
Opioid compounds affect a variety of hor-
mones and their functions and this has been 
termed opioid endocrinopathy. There are 
many investigations suggesting opioids can 
modulate the endocrine system (Benyamin 
et al., 2008; Hejazian et al., 2007; Katz, 
2005; Rhodin et al., 2010). Opioids can 
bind to opioid receptors in the hypothala-
mus, pituitary and testes and can cause re-
duction in the plasma level of testosterone, 
estrogen, cortisol, luetenizing hormone 
(LH) and gonadotropin releasing hormone 
(GnRH) (Katz, 2005; Benyamin et al., 
2008). 
Khademi et al. (2012) showed that opi-
um usage increases risk of mortality. The 
relationship between opium consumption 
and risk of coronary artery disease and its 
risk factors have been shown in previous 
studies (Masoumi et al., 2010a; Najafipour 
et al., 2010, 2012). Leptin and adiponectin 
are secreted along with some other hor-
mones such as apelin, tumor necrosis fac-
tor-α (TNF-α) and interleukin 6 (IL-6) from 
adipocytes in response to specific changes 
in certain body metabolic and physiologic 
conditions (Zhang et al., 1994; Maeda et al., 
1996). Leptin regulates energy homeostasis, 
appetite and metabolism of glucose and li-
pids (Havel, 2004; Meier, 2004). The level 
of leptin increases in some metabolic disor-
ders such as obesity, insulin resistance and 
dyslipidemia (Matsubara et al., 2000) which 
are cardiovascular disease (CVD) risk fac-
tors as well. Leptin enhances the calcifica-
tion of vascular cells of artery wall (Par-
hami et al., 2001) leading to atherosclerosis. 
Adiponectin is present in large amounts 
in plasma and accounts for 0.01 percent of 
human total plasma protein (Arita et al., 
1999). Several studies have previously 
shown that adiponectin level decreases in 
metabolic disorders and related diseases 
including obesity, type 2 diabetes mellitus 
(T2DM), insulin resistance, dyslipidemia 
and CVD (Matsubara et al., 2002; Margoni 
et al., 2011). It has also been mentioned in 
some reviews that adiponectin has remark-
able anti-diabetic, anti-atherogenic and anti-
inflammatory roles (Meier, 2004; Ka-
dowaki et al., 2006). 
Serum glucose has been shown to in-
crease after opium administration in rats 
(Asadikaram et al., 2008). Housova et al. 
(2005) showed that serum leptin and adi-
ponectin levels decreased in heroin addicts 
and methadone therapy for a year normal-
ized leptin level. 
To the best of our knowledge, there is 
no report regarding the effect of opium ad-
diction on serum levels of leptin and adi-
ponectin. As opium addiction is a CVD risk 
factor and adiponectin and leptin are im-
portant hormones influencing CVD risk 
factors, the present study was performed to 
investigate the effect of opium addiction on 
serum leptin and adiponectin levels in order 
to test the hypothesis that opium may wors-
en CVD diseases by causing changes in the 
production of these hormones. 
 
PATIENTS AND METHODS 
Participants 
The study subjects were randomly se-
lected from participants in a population-
based study, Kerman Coronary Artery Dis-
ease Risk factors Study (KERCADRS), in 
Kerman province of Iran in which 5900 of 
15 to 75 year old city residents were re-
cruited (Najafipour et al., 2012). For each 
group of opium addicts and non-addicts 
(healthy subjects), the sample size was cal-
culated to be 88. As the prevalence of opi-
um addiction is much higher in male sub-
jects and menstrual cycle may affect the 
serum concentration of hormones, only 
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male subjects were included in the study. 
This study was approved by the Ethic 
Committee of Kerman University of Medi-
cal Sciences (permission No 90/399 KA). 
Informed consent was obtained from all 
subjects participating in the study. 
 
Opium addiction definition 
Opium addiction was defined according 
to the DSM-IV criteria (American Psychiat-
ric Association, 2000). A physician, after 
medical examination and taking fasting 
blood sample, asked the participants to dis-
close whether they had ever used any type 
of drug. She/he assured them that the in-
formation will be analyzed anonymously 
and used only for research purposes. Al-
most all people in Iran trust on medical 
doctors in disclosing their confidential 
health related information. The opium ad-
dicted group were participants who dis-
closed that they were addicted to opium; 
therefore, there was no need to confirm 
their addiction by laboratory tests. Serum 
levels of adiponectin and leptin were meas-
ured by ELISA method (LaborDiagnostika 
Nord GmbH & Co. KG Leptin ELISA and 
Bender MedSystems GmbH eBioscience 
Adiponectin ELISA). 
 
Demographic and clinical variables 
The following variables were recorded 
for all participants: age, BMI [(defined as 
weight (kg) divided by the square of height 
(m2)]. BMI > 25 kg/m2 was considered ab-
normal. Cigarette smoking was categorized 
as current smoker and non-smoker. Other 
variables measured were hypertension 
(BP>140/90 mmHg), T2DM (Fasting blood 
glucose (FBS) ≥126 mg/dl measured twice) 
and dyslipidemia (serum cholesterol 
>240 mg/dl, high density lipoprotein (HDL) 
<35 mg/dl, low density lipoprotein (LDL) 
>130 mg/dl and serum triglyceride (TG) 
>200 mg/dl (NCEP III, 2002). LDL was 
calculated based on Friedewald formula: 
LDL = Total cholesterol – (HDL + TG/5) 
(Friedewald et al., 1972). 
Statistical analysis 
Data are presented as mean ± SD for 
quantitative variables and as absolute and 
relative frequencies for categorical varia-
bles. Normal distribution of data was as-
sessed by Kolmogorov-Smirnov test. Serum 
adiponectin and leptin levels were loga-
rithmically transformed to correct the 
skewness. Comparison between the two 
groups of the opium addict and non-addict 
subjects was analyzed using student’s t-test 
for quantitative variables and chi square test 
for categorical variables. For adjusting 
some potential variables such as age, ciga-
rette smoking, BMI, T2DM, hypertension, 
cholesterol, TG, HDL and LDL, multivari-
ate linear regression was used to determine 
association between opium addiction and 
serum adiponectin and leptin levels. Then, 
in order to find this association, we formed 
five linear regression models including 
Model 1) simple or unadjusted, Model 2) 
adjusted for age and BMI, Model 3) adjust-
ed for cigarette smoking, Model 4) adjusted 
for clinical variables including T2DM, hy-
pertension, cholesterol, TG, HDL and LDL, 
and finally Model 5) adjusted for all varia-
bles as final model. The two dependent var-
iables, adiponectin and leptin were not 
normally distributed, therefore we trans-
formed them to logarithmical values. Then 
log-transformed data was used regarding 
adiponectin and leptin in the linear regres-
sion models. Statistical analyses were per-
formed by STATA software, version 10 and 
P<0.05 was considered as statistically sig-
nificant. 
 
RESULTS 
A total of 176 subjects consisting of 88 
cases (addicted) and 88 controls (non-
addicted) men were enrolled in the study. A 
summary of descriptive and clinical charac-
teristics of participants is presented in Table 
1. (The complete individual data are pre-
sented in the form of two supplementary 
tables included in the electronic version of 
the MS). The two groups were only signifi-
cantly different regarding abnormal BMI 
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(≥ 25 kg/m2) so that 47.7 % of addicts 
compared to 67.8 % of non-addicts were 
overweight or obese (P value = 0.007). Dis-
tribution of age and frequency of cigarette 
smoking, hypertension, T2DM, having high 
cholesterol, TG and LDL and low HDL 
were similar between the two groups 
(P > 0.05). 
Mean and standard deviations for adi-
ponectin and leptin levels accompanied by 
their log-transformed distributions are also 
presented in Table 1. The adiponectin con-
centration in addicted subjects was signifi-
cantly lower than it was in non-addicts 
(P = 0.001). However, regarding leptin lev-
el, there was no statistically significant dif-
ference between the two groups (P = 0.80). 
 
Association between adiponectin and  
addiction 
According to the linear regression mod-
els in Table 2, by entering log-transformed 
values in the models, in the simple (unad-
justed) regression model, adiponectin con-
centration was significantly negatively as-
sociated with opium addiction (β = -0.131, 
P = 0.006).The model adjusted by all poten-
tial confounding variables (Model 5), con-
sisting of age, cigarette smoking, BMI, 
T2DM, Hypertension, Cholesterol, TG, 
HDL and LDL, also produced results simi-
lar to the unadjusted model (β = -0.144, 
P = 0.005). This means that there was still a 
negative significant association between 
addiction and decreased adiponectin level. 
When we fitted the regression model for the 
original data without log-transformed val-
ues, the similar results were obtained (β =  
-3014.1, P value = 0.001). Hence addiction, 
independent of other potential confounding 
variables had a significantly negative effect 
on the adiponectin level. The interaction 
between addiction and cigarette smoking on 
adiponectin concentration was not statisti-
cally significant (β = 0.13, P value = 0.184). 
None of the variables had a significant ef-
fect on adiponectin, based on the final re-
gression model (Table 2). 
 
Association between leptin and addiction 
In simple linear regression analyses 
(Model 1 in Table 2), no statistically signif-
icant association was found between serum 
leptin concentration and addiction status 
(β = -0.05, P = 0.52). After adjusting for 
potential confounding variables (Model 2 to 
5), there was still no association between 
addiction and leptin (β = 0.01, P = 0.95).  
 
 
 
Table 1: Comparison of descriptive and clinical characteristics in addicted and non-addicted groups 
 Control (non-addicts) (n = 88) 
Case (addicts) 
(n = 88) P value 
Age (year)* 42.5±4.8 43.8±4.3 0.063 
BMI (≥25kg/m2)** 59 (67.8) 42 (47.7) 0.007 
Cigarette smoking (current)** 34 (38.6) 45 (51.1) 0.096 
Hypertension (>140/90)** 19 (21.6) 20 (22.7) 0.85 
T2DM (FBG≥ 126 mg/dl)** 10 (11.4) 14 (15.9) 0.38 
Cholesterol (>240 mg/dl)** 12 (13.6) 13 (14.8) 0.82 
Triglyceride (>200 mg/dl)** 25 (28.4) 26 (29.5) 0.86 
HDL (<40 mg/dl)** 74 (84.1) 65 (73.9) 0.096 
LDL (>130 mg/dl ** 46 (52.3) 37 (42.0) 0.17 
Adiponectin (µg/ml)* 9.8±8.1 6.5±3.6 0.001 
Adiponectine (Log Transformed)* 0.86±0.33 0.72±0.30 0.006 
Leptin (ng/ml) * 11.8±10.3 11.5±10.8 0.80 
Leptin (Log Transformed )* 0.86±0.49 0.81±0.53 0.52 
*Mean ± SD,** n (%) 
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Table 2: Association between adiponectin and leptin with opium addiction 
 Adiponectin Leptin 
 β P value β P value 
Model 1* -0.131 0.006 -0.05 0.52 
Model 2* -0.133 0.007 0.33 0.83 
Model 3* -0.142 0.004 -0.24 0.88 
Model 4* -0.139 0.006 -0.70 0.65 
Model 5* -0.144 0.005 0.01 0.95 
Age -0.01 0.063 -0.002 0.76 
BMI -0.01 0.125 0.04 <0.001 
Cigarette smoking 0.065 0.198 -0.037 0.62 
Abnormal Cholesterol 0.109 0.15 0.151 0.195 
Abnormal TG -0.10 0.086 0.134 0.133 
Abnormal HDL -0.037 0.54 0.093 0.32 
Abnormal LDL 0.011 0.83 0.059 0.46 
T2DM (yes) 0.009 0.90 0.219 0.052 
Hypertension (yes) 0.028 0.64 -0.001 0.99 
*Log transformed values are used in the regression models: Model 1: simple (unadjusted), Model 2: 
adjusted for age and BMI, Model 3: adjusted for cigarette smoking, Model 4: adjusted for clinical vari-
ables (T2DM, Hypertension, Cholesterol, TG, HDL and LDL), Model 5: adjusted for all variables. 
 
 
 
By using the original data without being 
log-transformed, similar results were pro-
duced (β = 0.70, P value = 0.67, not shown 
in the Table). Interaction between addiction 
and cigarette smoking on leptin concentra-
tion was not statistically significant (β =  
-0.15, P = 0.32). The results of multivariate 
model (Model 5) demonstrated that except 
for BMI, which had significant positive ef-
fect (β = 0.04, P<0.001), none of other vari-
ables had a considerable effect on the serum 
leptin level. 
 
DISCUSSION 
The main finding of this study was that 
adiponectin level in opium addicts (even 
after adjusting for some potential confound-
ing variables) was lower than it was in non- 
addicts; while there was no statistically sig-
nificant difference between the two groups 
regarding leptin level. In fact, there was a 
negative association between opium addic-
tion and serum adiponectin concentration.  
It has been shown that adiponectin level 
increases in lean and decreases in obese 
subjects and that there is an inverse correla-
tion between adiponectin level and BMI 
(Weyer et al., 2001; Margoni et al., 2011). 
Here we showed that frequency of abnor-
mal BMI is significantly lower in opium 
addicts; and adiponectin concentration is 
also significantly lower in the addicts. Thus, 
due to the inverse association of adiponec-
tin with BMI, lower adiponectin in opium 
addicts cannot be inferred to their BMI 
(Meier, 2004; Kadowaki et al., 2006). On 
the other hand adiponectin is inversely cor-
related with obesity, but here in control 
group with higher BMI, adiponectin level 
was also significantly higher. Therefore, 
BMI is not the reason for lower adiponectin 
in addicted subjects either, and opium ad-
diction should be the main reason for the 
reduction in adiponectin level. As adiponec-
tin has shown anti-diabetic and anti-
atherogenic effects (Meier, 2004; Kadowaki 
et al., 2006), its reduction may account for 
the increased risk of CAD and metabolic 
disorders in opium users. In accordance 
with this finding, Mohammadi et al. (2009) 
reported that oral opium administration 
speeds up atherosclerosis formation in hy-
percholesterolemic rabbits. Interestingly, 
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Najafipour et al. (2010) reported that opi-
um, even in passive smoking form, in long 
term increases blood pressure and plasma 
lipids in rabbits. Two other studies have 
reported that current opium users have a 
higher risk of CAD (Masoumi et al., 2010b) 
and that opium consumption can increase 
the risk of heart attack and stroke (Asgary 
et al., 2008). 
In contrast to adiponectin, the results 
showed that serum leptin levels in opium 
addicts and healthy subjects did not differ. 
Serum leptin level is increased in subjects 
with metabolic disorders such as obesity 
and insulin resistance (Matsubara et al., 
2007). We expected that leptin level in con-
trol group to be higher due to higher BMI. 
Housova et al. (2005) has shown that serum 
leptin level is lower in heroin addicts and 
becomes normal after one year of metha-
done therapy. Moreover, positive correla-
tion of leptin level with BMI was lost in 
addicted group in their study. It has been 
well proven that circulating leptin increases 
in obesity (Matsubara et al., 2000). Our 
findings also support the fact that leptin 
level rises with increment of BMI (Table 
2); other factors did not show any signifi-
cant effects on leptin levels. The difference 
in the results of the two studies may be due 
to the effect of constituents other than mor-
phine, present in opium. This hypothesis 
needs more investigation to be proven. 
In this study we excluded female sub-
jects from the study. In our society, due to 
cultural reasons, the prevalence of opium 
addiction is much less (one fifth) in women 
in comparison to men (the prevalence in 
women was found to be 1.8 percent in 
KERCADR study (unpublished observa-
tions). Therefore, in addition to the changes 
in hormonal concentrations due to menstru-
al cycle in women, which might affect the 
leptin and adiponectin level, there was not 
enough opium addicted female samples to 
enter in the study.  
 
CONCLUSION 
Opium addiction may reduce adiponec-
tin levels. Since adiponectin has shown an-
ti-diabetic and anti-atherogenic effects, its 
reduction may account for increased risk of 
CVD and metabolic syndrome in opium 
users. As opium contains many alkaloids 
other than morphine, it seems necessary to 
conduct more investigations on the effect of 
opium components on leptin and adiponec-
tin levels. 
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